Atritech

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Atritech (Booth 1424) is featuring its Watchman Left Atrial Appendage (LAA) closure technology, for which the FDA recently accepted its pre-market approval application based on the data of the PROTECT AF trial.  

The Watchman LAA system is designed to keep harmful sized blood clots that form in the left atrial appendage from entering your blood stream, potentially causing stroke or other complications. It is designed to be permanently placed just behind or at the opening of the left atrial appendage.